Literature DB >> 18997816

New p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53.

S-H Min1, D M Kim, Y-S Heo, Y-I Kim, H M Kim, J Kim, Y-M Han, I-C Kim, O-J Yoo.   

Abstract

Most of the p53 target genes, all except MDM2, COP1 and PIRH2, perform functions in apoptosis, differentiation and cell cycle arrest. The aforementioned oncogenes downregulate p53 through a negative feedback mechanism, and thus contribute to tumor development. In this study, we report a new p53 target, PRL-1, which is believed to be a significant regulator in the development and metastasis of a variety of cancer types. Phosphatase of regenerating liver 1 (PRL-1) overexpression reduced the levels of endogenous and exogenous p53 proteins, and inhibited p53-mediated apoptosis. On the other hand, the ablation of PRL-1 by small interfering RNA (siRNA) increased p53 protein levels. The p53 downregulation was mediated by p53 ubiquitination and subsequent proteasomal degradation. Furthermore, p53 ubiquitination by PRL-1 was achieved through two independent pathways, by inducing PIRH2 transcription and by inducing MDM2 phosphorylation through Akt signaling. In addition, we showed that the PRL-1 gene harbors a p53 response element in the first intron, and its transcription is regulated by the p53 protein. These findings imply that the new oncogenic p53 target, PRL-1, may contribute to tumor development by the downregulation of p53 by a negative feedback mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997816     DOI: 10.1038/onc.2008.409

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

Review 1.  Tied up in loops: positive and negative autoregulation of p53.

Authors:  Xin Lu
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

2.  Structural Basis of the Oncogenic Interaction of Phosphatase PRL-1 with the Magnesium Transporter CNNM2.

Authors:  Paula Giménez-Mascarell; Iker Oyenarte; Serge Hardy; Tilman Breiderhoff; Marchel Stuiver; Elie Kostantin; Tammo Diercks; Angel L Pey; June Ereño-Orbea; María Luz Martínez-Chantar; Reham Khalaf-Nazzal; Felix Claverie-Martin; Dominik Müller; Michel L Tremblay; Luis Alfonso Martínez-Cruz
Journal:  J Biol Chem       Date:  2016-11-29       Impact factor: 5.157

3.  Increased expression of PRL-1 protein correlates with shortened patient survival in human hepatocellular carcinoma.

Authors:  J-W Lu; J-G Chang; K-T Yeh; R-M Chen; J J P Tsai; W-W Su; R-M Hu
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

Review 4.  MDM2-p53 pathway in hepatocellular carcinoma.

Authors:  Xuan Meng; Derek A Franklin; Jiahong Dong; Yanping Zhang
Journal:  Cancer Res       Date:  2014-12-04       Impact factor: 12.701

Review 5.  Phosphatase of regenerating liver: a novel target for cancer therapy.

Authors:  Amanda M Campbell; Zhong-Yin Zhang
Journal:  Expert Opin Ther Targets       Date:  2014-03-01       Impact factor: 6.902

6.  The Regulation of Multiple p53 Stress Responses is Mediated through MDM2.

Authors:  Wenwei Hu; Zhaohui Feng; Arnold J Levine
Journal:  Genes Cancer       Date:  2012-03

Review 7.  Protein tyrosine phosphatases as potential therapeutic targets.

Authors:  Rong-Jun He; Zhi-Hong Yu; Ruo-Yu Zhang; Zhong-Yin Zhang
Journal:  Acta Pharmacol Sin       Date:  2014-09-15       Impact factor: 6.150

8.  Gene expression profiling of peripheral blood mononuclear cells in the setting of peripheral arterial disease.

Authors:  Rizwan Masud; Khader Shameer; Aparna Dhar; Keyue Ding; Iftikhar J Kullo
Journal:  J Clin Bioinforma       Date:  2012-03-12

9.  Host Kinase Activity is Required for Coxiella burnetii Parasitophorous Vacuole Formation.

Authors:  S Kauser Hussain; Laura J Broederdorf; Uma M Sharma; Daniel E Voth
Journal:  Front Microbiol       Date:  2010-12-23       Impact factor: 5.640

10.  Drosophila PRL-1 is a growth inhibitor that counteracts the function of the Src oncogene.

Authors:  Krystle T Pagarigan; Bryce W Bunn; Jake Goodchild; Travis K Rahe; Julie F Weis; Leslie J Saucedo
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.